{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-016298","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2023-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.004166+00:00","generated_at":"2026-06-20T08:16:27.949743+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"4DMT reports pipeline progress; Fabry trial halted after aHUS, FDA aligns on endpoints","bullets":["Filed IND for Phase 2 SPECTRA trial of 4D-150 in DME; enrollment expected Q3 2023.","Initiated randomized Phase 2 PRISM trial in wet AMD; 50 patients, 2:2:1 vs aflibercept.","Fabry program: 3 aHUS cases among 6 patients; one grade 4 DLT requiring hemodialysis.","Cardiac efficacy promising: improvements in peak VO2, KCCQ, GLS in evaluable patients.","FDA aligned on pivotal endpoints (peak VO2, KCCQ); co. halts enrollment, will re-evaluate in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-016298","json":"https://secwatch.observer/filing/0001193125-23-016298.json","markdown":"https://secwatch.observer/filing/0001193125-23-016298.md","text":"https://secwatch.observer/filing/0001193125-23-016298.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312523016298/0001193125-23-016298-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312523016298/d427358d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T08:16:27.949743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}